Atopic Dermatitis: Dupilumab, JAK Inhibitors, and Emerging Therapies
Dupilumab: The Biologic Standard of Care
Dupilumab, an anti-IL-4/IL-13 monoclonal antibody, established the biologic era for atopic dermatitis (AD). The SOLO 1 and SOLO 2 trials demonstrated that dupilumab 300 mg every 2 weeks achieved IGA 0/1 (clear/almost clear) in 36-38% of patients versus 8-10% with placebo at 16 weeks, with EASI-75 response in 44-51%. Long-term data from LIBERTY AD CHRONOS show sustained efficacy through 52 weeks with an acceptable safety profile. The most notable adverse effect is conjunctivitis (8-25% in trials), managed with artificial tears, topical cyclosporine, or tacrolimus eye drops. Dupilumab is FDA-approved for patients aged 6 months and older.
JAK Inhibitors: Oral Options with Rapid Onset
Three oral JAK inhibitors are approved for moderate-to-severe AD: abrocitinib (JAK1-selective), upadacitinib (JAK1-selective), and baricitinib (JAK1/JAK2). In head-to-head trials, upadacitinib 30 mg demonstrated superiority to dupilumab for EASI-75 at week 16 (71% vs 61%, p = 0.006) in the Heads Up trial. Abrocitinib 200 mg showed similar superiority to dupilumab in JADE DARE (EASI-90 at week 4: 29% vs 15%). JAK inhibitors offer faster onset of action (significant itch reduction within 2-4 days) compared to dupilumab (2-4 weeks). However, the JAK inhibitor safety profile requires consideration of the ORAL Surveillance-related class warnings including cardiovascular risk, VTE, and malignancy, necessitating appropriate screening and monitoring.
Tralokinumab and Emerging Biologics
Tralokinumab, a selective IL-13 inhibitor, achieved IGA 0/1 in 15.8-22.2% and EASI-75 in 25-33.2% as monotherapy (ECZTRA trials), with improved efficacy when combined with topical corticosteroids (EASI-75 of 56%). Lebrikizumab, another IL-13 inhibitor with a longer dosing interval (every 4 weeks after loading), achieved IGA 0/1 in 33.2-38.4% in the ADvocate trials. Nemolizumab (anti-IL-31 receptor) is advancing through Phase 3 trials with particularly strong efficacy for pruritus, the most bothersome AD symptom, achieving a 42.8% improvement in peak pruritus NRS at week 16.
Sponsored
Treatment Algorithm: Positioning Systemic Therapies
For moderate-to-severe AD uncontrolled by optimized topical therapy, dupilumab remains the preferred first-line systemic option for most patients given its established long-term safety and efficacy across ages. JAK inhibitors are preferred when rapid onset is critical (severe itch impacting sleep, quality of life), in patients who prefer oral medication, or in dupilumab non-responders. For patients with JAK inhibitor safety concerns (age over 65, cardiovascular risk factors, smoking history, malignancy history), dupilumab or tralokinumab is preferred. Cyclosporine and methotrexate remain bridge therapy options while awaiting biologic access.
Topical JAK Inhibitors and Adjunctive Care
Topical ruxolitinib 1.5% cream (Opzelura) is FDA-approved for mild-to-moderate AD in patients 12 years and older, offering a non-steroidal topical option with IGA success rates of 50-53% at 8 weeks (TRuE-AD trials). Application is limited to 20% BSA to minimize systemic absorption. Regardless of systemic therapy choice, daily emollient use, trigger avoidance, and proactive topical anti-inflammatory therapy (twice-weekly TCS or TCI to previously affected areas) remain the foundation of AD management.
Sponsored
Want to try Ailva?
Ailva is a clinical intelligence platform that delivers evidence-based answers with verified citations and cross-system reasoning. Free for all NPI holders.